標(biāo)題: Titlebook: Innovations for Next-Generation Antibody-Drug Conjugates; Marc Damelin Book 2018 Springer International Publishing AG, part of Springer Na [打印本頁] 作者: 和善 時(shí)間: 2025-3-21 16:58
書目名稱Innovations for Next-Generation Antibody-Drug Conjugates影響因子(影響力)
書目名稱Innovations for Next-Generation Antibody-Drug Conjugates影響因子(影響力)學(xué)科排名
書目名稱Innovations for Next-Generation Antibody-Drug Conjugates網(wǎng)絡(luò)公開度
書目名稱Innovations for Next-Generation Antibody-Drug Conjugates網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Innovations for Next-Generation Antibody-Drug Conjugates被引頻次
書目名稱Innovations for Next-Generation Antibody-Drug Conjugates被引頻次學(xué)科排名
書目名稱Innovations for Next-Generation Antibody-Drug Conjugates年度引用
書目名稱Innovations for Next-Generation Antibody-Drug Conjugates年度引用學(xué)科排名
書目名稱Innovations for Next-Generation Antibody-Drug Conjugates讀者反饋
書目名稱Innovations for Next-Generation Antibody-Drug Conjugates讀者反饋學(xué)科排名
作者: synovial-joint 時(shí)間: 2025-3-21 21:45
Cancer Drug Discovery and Developmenthttp://image.papertrans.cn/i/image/467020.jpg作者: DIKE 時(shí)間: 2025-3-22 00:49 作者: ICLE 時(shí)間: 2025-3-22 05:53
Innovations for Next-Generation Antibody-Drug Conjugates978-3-319-78154-9Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: 羞辱 時(shí)間: 2025-3-22 10:26 作者: 比目魚 時(shí)間: 2025-3-22 14:10
?These conditions can lead to neck pain and/or neurological deficit that can significantly compromise an individual’s quality of life. ?Despite the regularity of these conditions, there remains both uncertainty and controversy regarding optimal management. ?No standard of care exists, however there作者: Minutes 時(shí)間: 2025-3-22 19:00
Marc Damelinrovide practical applications of the chapters key points.WriDegenerative disorders of the cervical spine are among the more common reasons why patients seek medical attention or consult with a spine specialist. ?These conditions can lead to neck pain and/or neurological deficit that can significantl作者: 糾纏 時(shí)間: 2025-3-22 23:03
Aman P. Singh,Dhaval K. Shahesearch, held in Alicante, Spain. The success of this first meeting led to the second held, two years later in Sendai, Japan, organized as a satellite of the VII ISER. We were fortunate that these meetings began at a time of vigorous research activity in the area of retinal degenerations, thanks to 作者: 西瓜 時(shí)間: 2025-3-23 03:25
Elizabeth VanAlphen,Omar Perezsst in welcher Situation die besten Behandlungsergebnisse er.Der Weg zur richtigen Therapieentscheidung in der HWS-Chirurgie. Zur Behandlung degenerativer Erkrankungen der Halswirbels?ule hat sich eine Vielzahl unterschiedlicher Verfahren mit spezifischen Indikationen, Vor- und Nachteilen entwickelt作者: faculty 時(shí)間: 2025-3-23 08:28 作者: cuticle 時(shí)間: 2025-3-23 11:38
Frank Comer,Changshou Gao,Steve Coatsntralis. Iodoacetate (IA) was administered by subretinal injection in the area centralis. Subretinal delivery involved injection of IA into the subretinal space of a 4 mm diameter retinal bleb, using a dose of 0.1, 1, 1.6, 2 or 5 μg IA/bleb. IA was dissolved in 50 μl of BSS or a viscous hyaluronate 作者: 剛毅 時(shí)間: 2025-3-23 15:23 作者: NEEDY 時(shí)間: 2025-3-23 20:04
Alberto Dal Corso,Samuele Cazzamalli,Dario Neriach written by the world renowned experts.Still valid and usA renewed interest in aliphatic polyesters has resulted in developing materials important in the biomedical and ecological fields. Mainly materials such as PLA and PCL homopolymers have so far been used in most applications. There are many 作者: CHURL 時(shí)間: 2025-3-23 23:53 作者: archetype 時(shí)間: 2025-3-24 03:05
e groups along the main chains. Initial studies of biodegradation mechanisms were motivated by biomedical applications of biodegradable polymers. In recent years polymer waste management through biodegradation and bioconversion has become more important..The presence of hydrolysable and/or oxidizabl作者: 精密 時(shí)間: 2025-3-24 06:58 作者: Entrancing 時(shí)間: 2025-3-24 12:20 作者: FLAT 時(shí)間: 2025-3-24 16:29 作者: 令人發(fā)膩 時(shí)間: 2025-3-24 19:28 作者: Interim 時(shí)間: 2025-3-25 00:17 作者: 沒血色 時(shí)間: 2025-3-25 04:17 作者: 建筑師 時(shí)間: 2025-3-25 09:56 作者: Inkling 時(shí)間: 2025-3-25 13:12 作者: carotenoids 時(shí)間: 2025-3-25 17:46 作者: pus840 時(shí)間: 2025-3-25 21:00 作者: 恃強(qiáng)凌弱 時(shí)間: 2025-3-26 00:38
Bispecific and Biparatopic Antibody Drug Conjugates,in the early 1900’s the concept of a “magic bullet”, an ideal therapeutic that would specifically target a disease-causing agent without causing harm to the body. This concept still underpins the overarching goal of biopharmaceutical development today: to produce drugs that have a broad therapeutic 作者: irreparable 時(shí)間: 2025-3-26 06:01 作者: xanthelasma 時(shí)間: 2025-3-26 11:47
Antibody-Drug Conjugates: Targeting the Tumor Microenvironment,th the aim to increase anti-cancer activity and spare normal tissues from undesired toxicity. Until recently, most ADC development activities have focused on the use of monoclonal antibodies, capable of selective binding and internalization into the target tumor cells. However, in principle, it woul作者: compassion 時(shí)間: 2025-3-26 15:25
Next Horizons: ADCs Beyond Oncology,eyond oncology. The key variables for oncology ADCs in terms of the targeted cell type, targeting strategy, and payload are often clearer while the corresponding elements for non-oncology indications are more complex. Challenges in designing such non-oncology ADCs include selecting the targeting cel作者: arboretum 時(shí)間: 2025-3-26 17:31 作者: 大方一點(diǎn) 時(shí)間: 2025-3-27 00:06 作者: 空中 時(shí)間: 2025-3-27 04:11
Combining ADCs with Immuno-Oncology Agents,nogenic cell death (ICD), which leads to potent stimulation of effector T-cell activation as well as their recruitment into tumors. It has been recently demonstrated that some ADC payloads are also able to elicit ICD. Furthermore, several cytotoxic warheads used in ADCs can directly induce dendritic作者: detach 時(shí)間: 2025-3-27 09:16
Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Devssful application of this tool can not only enhance the scientific understanding of the processes underlying PK-PD of ADCs but can also provide comprehensive model-derived outcomes that can help accelerate the decision-making process. Within this book chapter, we have discussed an array of different作者: 擁護(hù) 時(shí)間: 2025-3-27 11:01
HER2-Targeted ADCs: At the Forefront of ADC Technology Development,different drug linkers, drug to antibody ratios, site-specific antibody drug conjugates, and biparatopic antibody drug conjugates. Anti-HER2 antibody drug conjugates currently in clinical testing are described. Promising early clinical data are emerging from some of the ADCs employing novel technolo作者: 興奮過度 時(shí)間: 2025-3-27 16:54 作者: 金桌活畫面 時(shí)間: 2025-3-27 21:33
Next Horizons: ADCs Beyond Oncology, account for designing ADCs for non-oncology indications, including payload and antibody selection. With the evolution of ADC platform and technology, more ADCs for non-oncology indications are yet to be developed.作者: 一窩小鳥 時(shí)間: 2025-3-28 01:25
and biomechanics as well as the pathophysiologyleading to various cervical degenerative disorders and the possible neurological sequelae. ?Subsequent chapters outline characteristics of the clinical presentation and the various diagnostic modalities to evaluate these patients. ?Key elements involved作者: GRAVE 時(shí)間: 2025-3-28 04:38 作者: Instrumental 時(shí)間: 2025-3-28 09:12
Frank Comer,Changshou Gao,Steve Coatsspace and promoted a localized IA effect. Subretinal IA dissolved in BSS caused less severe and less consistent PR degeneration. Healon? or BSS alone did not induce PR damage. Thus, a model with PR-lacking area centralis has been created by subretinal injection of IA with a viscous solution. This mo作者: crease 時(shí)間: 2025-3-28 12:25
Jack Lin,Jason Sagerts of novel polymers with inherent environmentally favorable properties such as renewability and degradability and a series of interesting monomers found in the metabolisms and cycles of nature are given.978-3-642-07597-1978-3-540-45734-3Series ISSN 0065-3195 Series E-ISSN 1436-5030 作者: 正面 時(shí)間: 2025-3-28 16:49
Alberto Dal Corso,Samuele Cazzamalli,Dario Neris of novel polymers with inherent environmentally favorable properties such as renewability and degradability and a series of interesting monomers found in the metabolisms and cycles of nature are given.978-3-642-07597-1978-3-540-45734-3Series ISSN 0065-3195 Series E-ISSN 1436-5030 作者: 臆斷 時(shí)間: 2025-3-28 22:06 作者: 座右銘 時(shí)間: 2025-3-28 23:19
g prior to the degradation of the crystalline and cross-linked regions. Cross-linked polymers containing one or more hydrolysable functional groups (amides, enamine, enol-ketone, ester, urea and urethane) have been synthesized and found to be biodegradable at various rates. They show great promise f作者: 火光在搖曳 時(shí)間: 2025-3-29 06:55
Marc Damelinsorders and the possible neurological sequelae. ?Subsequent chapters outline characteristics of the clinical presentation and the various diagnostic modalities to evaluate these patients. ?Key elements involved978-3-319-97952-6作者: 出生 時(shí)間: 2025-3-29 07:26
Elizabeth VanAlphen,Omar Perezum wichtigen Aspekt der Implantatsicherheit und zu den m?glichen Komplikationen sowie ein Ausblick auf zukünftige Entwicklungen runden die Darstellung ab..Umfassend, fundiert und reich illustriert – alle Aspekt978-3-662-43562-5作者: vertebrate 時(shí)間: 2025-3-29 14:12 作者: 有惡意 時(shí)間: 2025-3-29 16:12
2196-9906 of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies.? These innovations will inspire and educate scientists who are designing next-generation ADCs978-3-030-08627-5978-3-319-78154-9Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: 偏見 時(shí)間: 2025-3-29 19:55
Philipp Müller,Jonathan Rios-Doria,Jay Harper,Anthony Cao作者: allergen 時(shí)間: 2025-3-30 03:45
Magali Guffroy,Hadi Falahatpisheh,Martin Finkelstein作者: 品嘗你的人 時(shí)間: 2025-3-30 06:36 作者: Merited 時(shí)間: 2025-3-30 11:52
Introduction: Motivations for Next-Generation ADCs,innovations of next-generation ADCs described throughout the volume. A framework for designing and interpreting preclinical pharmacology studies is proposed such that emerging technologies can be rigorously evaluated and molecules can be judiciously optimized.作者: 下垂 時(shí)間: 2025-3-30 16:01 作者: 無法治愈 時(shí)間: 2025-3-30 19:38
Targeting Drug Conjugates to the Tumor Microenvironment: Probody Drug Conjugates,making antibody prodrugs that have been or could be used to selectively deliver drug to a tumor compared to normal tissues. These technologies have the potential to lower on-target, off-tumor toxicities and enable better efficacy of ADCs due to better target selection and the delivery of higher concentrations of drug to tumors.
